Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 JAK2 V617F Mutation is uncommon in chronic myelomonocytic leukaemia.

× No keyword cloud information.

6 in total

1. Incidence and significance of the JAK2 V617F mutation in patients with chronic myeloproliferative disorders.

Authors: S E Langabeer; F Ni Ainle; E Conneally; M Lawler
Journal: Ir J Med Sci Date: 2007-04-18 Impact factor: 1.568

Review 2. JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology.

Authors: David P Steensma
Journal: J Mol Diagn Date: 2006-09 Impact factor: 5.568

Review 3. The JAK2(V617F) tyrosine kinase mutation in myeloproliferative disorders: Summary of published literature and a perspective.

Authors: Martha Wadleigh; D Gary Gilliland
Journal: Curr Hematol Malig Rep Date: 2006-06 Impact factor: 3.952

4. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation.

Authors: Hadrian Szpurka; Ramon Tiu; Gurunathan Murugesan; Samer Aboudola; Eric D Hsi; Karl S Theil; Mikkael A Sekeres; Jaroslaw P Maciejewski
Journal: Blood Date: 2006-06-01 Impact factor: 22.113

5. The implication of identifying JAK2 ( V617F ) in myeloproliferative neoplasms and myelodysplastic syndromes with bone marrow fibrosis.

Authors: Randall J Olsen; Cherie H Dunphy; Dennis P O'Malley; Lawrence Rice; April A Ewton; Chung-Che Chang
Journal: J Hematop Date: 2008-08-28 Impact factor: 0.196

6. Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders.

Authors: C Walz; N C P Cross; R A Van Etten; A Reiter
Journal: Leukemia Date: 2008-06-05 Impact factor: 11.528

6 in total